Amyotrophic lateral sclerosis: Update for family physicians

Canadian Family Physician

Volumn 52, Issue 12, 2006, Pages 1563-1569

  Shoesmith, Christen L ^a   Strong, Michael J ^a,b,c,d  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b London Motor Neuron Diseases Clinic   (United Kingdom)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; ARUNDIC ACID; CEFTRIAXONE; CREATINE; GABAPENTIN; LAMOTRIGINE; MEMANTINE; MINOCYCLINE; RECOMBINANT SOMATOMEDIN C; RILUZOLE; TAMOXIFEN; THALIDOMIDE; TOPIRAMATE; UBIDECARENONE;

AMINOTRANSFERASE BLOOD LEVEL; AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIAL; DIET THERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DYSARTHRIA; DYSPHAGIA; ELECTROPHYSIOLOGY; FATIGUE; GENERAL PRACTITIONER; HUMAN; INCIDENCE; LIMB WEAKNESS; NAUSEA; NUTRITION; OXYGEN THERAPY; PATHOGENESIS; PHYSICAL EXAMINATION; QUALITY OF LIFE; REVIEW; SIDE EFFECT; STEM CELL TRANSPLANTATION; SURVIVAL;

AMYOTROPHIC LATERAL SCLEROSIS; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; ENTERAL NUTRITION; FAMILY PRACTICE; HUMANS; NUTRITION ASSESSMENT; PROGNOSIS;

EID: 33845867118     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Rowland LR. Clinical aspects of sporadic amyotrophic lateral sclerosis/motor neuron disease. In: Shaw PJ, Strong MJ, editors. Motor neuron disorders. Philadelphia, Pa: Butterworth Heinemann; 2003. p. 111-43.
2. Strong MJ, Kesavapany S, Pant HC. The pathobiology of amyotrophic lateral sclerosis: a proteinopathy? J Neuropathol Exp Neurol 2005;64(8):649-64.
3. Armon C. Epidemiology of amyotrophic lateral sclerosis/motor neuron disease. In: Shaw PJ, Strong MJ, editors. Motor neuron disorders. Philadelphia, Pa: Butterworth Heinemann; 2003. p. 167-205.
4. Belli S, Vanacore N. Proportionate mortality of Italian soccer players: is amyotrophic lateral sclerosis an occupational disease? Eur J Epidemiol 2005;20(3):237-42.
5. Weydt P, Moller T. Neuroinflammation in the pathogenesis of amyotrophic lateral sclerosis. Neuroreport 2005;16(6):527-31.
6. Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;(5):293-9.
7. Ross MA, Miller RG, Berchert L, Parry G, Barohn RJ, Armon C, et al. Toward earlier diagnosis of amyotrophic lateral sclerosis: revised criteria. rhCNTF ALS Study Group. Neurology 1998;50(3):768-72.
8. Pioro EP. Neuroimaging in motor neuron disorders. In: Shaw PJ, Strong MJ, editors. Motor neuron disorders. Philadelphia, Pa: Butterworth Heinemann; 2003. p. 73-108.
9. Ross MA. Clinical features and diagnosis of amyotrophic lateral sclerosis. In: Mancall EL, editor. Continuum: amyotrophic lateral sclerosis. Philadelphia, Pa: Lippincott, Williams & Williams; 2002. p. 9-31.
10. Ringholz GM, Appel SH, Bradshaw M, Cooke NA, Mosnik DM, Schulz PE. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology 2005;65(4):586-90.
11. Strong MJ, Lomen-Hoerth C, Caselli RJ, Bigio EH, Yang W. Cognitive impairment, frontotemporal dementia, and the motor neuron diseases. Ann Neurol 2003;54(Suppl 5):20-3.
12. Strong MJ. The basic aspects of therapeutics in amyotrophic lateral sclerosis. Pharmacol Ther 2003;98(3):379-414.
13. Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000. J Neurol Neurosurg Psychiatry 2003;74(9):1258-61.
14. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2002; (2) :CD001447.
15. Orrell RW, Lane RJ, Ross M. Antioxidant treatment for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2005; (1) :CD002829.
16. Mitchell JD, Wokke JH, Borasio GD. Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2002;(3):CD002064.
17. McGeer EG, McGeer PL. Pharmacologic approaches to the treatment of amyotrophic lateral sclerosis. Biodrugs 2005;19(1):31-7.
18. Ryu H, Smith K, Camelo SI, Carreras I, Lee J, Iglesias AH, et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem 2005;93(5):1087-98.
19. Brown RH Jr. Amyotrophic lateral sclerosis-a new role for old drugs. N Engl J Med 2005;352(13):1376-8.
20. Rothstein JD, Patel S, Regan MR, Haenggli C, Huang YH, Bergles DE, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005;433(7021):73-7.
21. Silani V, Cova L, Corbo M, Ciammola A, Polli E. Stem-cell therapy for amyotrophic lateral sclerosis. Lancet 2004;364(9429):200-2.
22. Aboussouan LS, Khan SU, Meeker DP, Stelmach K, Mitsumoto H. Effect of noninvasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis. Ann Intern Med 1997;127(6):450-3.
23. Kleopa KA, Sherman M, Neal B, Romano GJ, Heiman-Patterson T. Bipap improves survival and rate of pulmonary function decline in patients with ALS. J Neurol Sci 1999;164(1):82-8.
24. Pinto AC, Evangelista T, Carvalho M, Alves MA, Sales Luis ML. Respiratory assistance with a non-invasive ventilator (Bipap) in MND/ALS patients: survival rates in a controlled trial. J Neurol Sci 1995;129(Suppl):19-26.
25. Jackson CE, Rosenfeld J, Moore DH, Bryan WW, Barohn RJ, Wrench M, et al. A preliminary evaluation of a prospective study of pulmonary function studies and symptoms of hypoventilation in ALS/MND patients. J Neurol Sci 2001;191(1-2):75-8.
26. Miller RG, Rosenberg JA, Gelinas DF, Mitsumoto H, Newman D, Sufit R, et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology 1999;52(7):1311-23.
27. Desport JC, Mabrouk T, Bouillet P, Perna A, Preux PM, Couratier P. Complications and survival following radiologically and endoscopically-guided gastrostomy in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2005;6(2):88-93.
28. Mitsumoto H, Davidson M, Moore D, Gad N, Brandis M, Ringel S, et al. Percutaneous endoscopic gastrostomy (PEG) in patients with ALS and bulbar dysfunction. Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4(3):177-85.
29. Strong MJ, Rowe A, Rankin RN. Percutaneous gastrojejunostomy in amyotrophic lateral sclerosis. J Neurol Sci 1999;169(1-2):128-32.
30. Chio A, Finocchiaro E, Meineri P, Bottacchi E, Schiffer D. Safety and factors related to survival after percutaneous endoscopic gastrostomy in ALS. Neurology 1999;53(5):1123-5.
31. Demaerschalk BM, Strong MJ. Amyotrophic lateral sclerosis. Curr Treat Options Neurol 2000;2:13-22.
32. Forshew D, Bromberg M. A survey of clinicians' practice in the symptomatic treatment of ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4(4):258-63.
33. Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A, Bui C. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 2003;327(7414):523-8.
34. Bruera E, de Stoutz N, Velasco-Leiva A, Schoeller T, Hanson J. Effects of oxygen on dyspnoea in hypoxaemic terminal-cancer patients. Lancet 1993;342(8862):13-4.
35. Ashworth NL, Satkunam LE, Deforge D. Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2004;1:CD004156.
36. Orsnes GB, Sorensen PS, Larsen TK, Ravnborg M. Effect of baclofen on gait in spastic MS patients. Acta Neurol Scand 2000;101(4):244-8.
37. Bass B, Weinshenker B, Rice GP, Noseworthy JH, Cameron MG, Hader W, et al. Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. Can J Neurol Sci 1988;15(1):15-9.
38. Roussan M, Terrence C, Fromm G. Baclofen versus diazepam for the treatment of spasticity and long-term follow-up of baclofen therapy. Pharmatherapeutica 1985;4(5):278-84.
39. Connolly PS, Shirley EA, Wasson JH, Nierenberg DW. Treatment of nocturnal leg cramps. A crossover trial of quinine vs vitamin E. Arch Intern Med 1992;152(9):1877-80.
40. Khajehdehi P, Mojerlou M, Behzadi S, Rais-Jalali GA. A randomized, double-blind, placebo-controlled trial of supplementary vitamins E, C and their combination for treatment of haemodialysis cramps. Nephrol Dial Transplant 2001;16(7):1448-51.
41. Mueller ME, Gruenthal M, Olson WL, Olson WH. Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch Phys Med Rehabil 1997;78(5):521-4.
42. Diener HC, Dethlefsen U, Dethlefsen-Gruber S, Verbeek P. Effectiveness of quinine in treating muscle cramps: a double-blind, placebo-controlled, parallel-group, multicentre trial. Int J Clin Pract 2002;56(4):243-6.
43. Iannaccone S, Ferini-Strambi L. Pharmacologic treatment of emotional lability. Clin Neuropharmacol 1996;19(6):532-5.
44. Szczudlik A, Slowik A, Tomik B. [The effect of amitriptyline on the pathological crying and other pseudobulbar signs]. Neurol Neurochir Pol 1995;29(5):663-74.
45. Schiffer RB, Herndon RM, Rudick RA. Treatment of pathologic laughing and weeping with amitriptyline. N Engl J Med 1985;312(23):1480-2.
46. Brooks BR, Thisted RA, Appel SH, Bradley WG, Olney RK, Berg JE, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology 2004;63(8):1364-70.
47. Lewis DW, Fontana C, Mehallick LK, Everett Y. Transdermal scopolamine for reduction of drooling in developmentally delayed children. Dev Med Child Neurol 1994;36(6):484-6.
48. Andersen PM, Gronberg H, Franzen L, Funegard U. External radiation of the parotid glands significantly reduces drooling in patients with motor neuron disease with bulbar paresis. J Neurol Sci 2001;191(1-2):111-4.
49. Harriman M, Morrison M, Hay J, Revonta M, Eisen A, Lentle B. Use of radiotherapy for control of sialorrhea in patients with amyotrophic lateral sclerosis. J Otolaryngol 2001;30(4):242-5.
50. Hyson C, Johnson AM, Jog MS. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Move Disord 2002;17(6):1318-20.
51. Giess R, Naumann M, Werner E, Riemann R, Beck M, Puls I, et al. Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2000;69(1):121-3.
52. Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G. A randomized trial of botulinum toxin A for treatment of drooling. Neurology 2003;61(9):1279-81.
53. Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 2004;62(1):37-40.
54. Mazzocato C, Buclin T, Rapin CH. The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: a randomized double-blind controlled trial. Ann Oncol 1999;10(12):1511-4.